METiS Therapeutics has passed its listing hearing and is preparing for an initial public offering (IPO) on the Hong Kong Stock Exchange (HKEX) under Chapter 18C rules, positioning itself to become the first AI-driven drug delivery company listed in the market. The IPO is jointly sponsored by Jefferies, Deutsche Securities Asia, and CITIC Securities. The company has built a proprietary AI platform, NanoForge, which integrates AI models, a vast proprietary lipid library and high-throughput experimental systems to design and optimise nanomaterial-based delivery systems for macromolecular drugs, such as nucleic acids and proteins.

The company's pipeline includes over ten programs, with the most advanced, MTS-004, a drug for pseudobulbar affect (PBA), completing Phase III trials. Its business model combines platform partnerships with pharmaceutical companies and product licensing. Recent milestones include a licensing deal worth up to RMB 1.8 billion (USD 265 million) for MTS-004 and a pipeline candidate, MTS-105, that has shown promise in preclinical studies for delivering mRNA-encoded bispecific antibodies (BsAbs) directly to the liver for cancer treatment.

According to PharmCube's MedAlpha® database, METiS has reported USD 437 million raised in previous financing events. Click here to request a free trial for MedAlpha®.